IRF1 and cancer: The IFN-γ-mediated PD-L1 upregulation occurs mainly through JAK/STAT/IRF1 signaling pathway activation in several types of cancers, including NSCLC, resulting in binding of IRF1 to the CD274 promoter [61,100,105,106].